Cart
sales@molnova.com
Linzagolix
CAS No. 935283-04-8
Linzagolix( —— )
Catalog No. M27897 CAS No. 935283-04-8
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 431 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinzagolix
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
-
DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number935283-04-8
-
Formula Weight508.42
-
Molecular FormulaC22H15F3N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (245.86 mM)
-
SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Trujillo C, Goya P, Rozas I. Study of Meldrum's Acid Cyclization Reactions. J Phys Chem A. 2018 Mar 8;122(9):2535-2541.
molnova catalog
related products
-
LCMV gp33-41 (TFA)
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.
-
Kv3, Channel Contain...
Kv3 channel protein is expressed by parvalbumin (PV)-containing pallidal neurons.Kv3, Channel Containing Protein (567-585) corresponds to amino acids 567 to 585 fragment of the Kv3.1b channel containing protein.
-
Influenza NP (147-15...
This peptide is a H2-Db-restricted epitope from Influenza nucleoprotein (147-155).
